Cargando…

Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) is the second most frequent type of primary liver cancer. ICC is among the deadliest malignancies, highlighting that novel treatments are urgently needed. Studies have shown that CD44 variant isoforms, rather than the CD44 standard isoform, are selectively expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bei, Yuncheng, He, Jian, Dong, Xuhui, Wang, Yuxin, Wang, Sijie, Guo, Wan, Cai, Chengjie, Xu, Zhiye, Wei, Jia, Liu, Baorui, Zhang, Nan, Shen, Pingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Therapeutic Development and Chemical Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345965/ https://www.ncbi.nlm.nih.gov/pubmed/37205633 http://dx.doi.org/10.1158/0008-5472.CAN-23-0510

Ejemplares similares

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
por: Shi, Jing, et al.
Publicado: (2023)

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
por: Boreddy, Srinivas Reddy, et al.
Publicado: (2023)

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
por: Ludwig, Michael P., et al.
Publicado: (2023)

CD86(+)/CD206(+) tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma
por: Sun, Dalong, et al.
Publicado: (2020)

The construction of intrahepatic cholangiocarcinoma model in zebrafish
por: Wang, Jing, et al.
Publicado: (2017)

CD44(+)CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
por: Hurt, E M, et al.
Publicado: (2008)

CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2
por: Chang, G, et al.
Publicado: (2014)

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
por: Marangoni, E, et al.
Publicado: (2009)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
por: Chen, H, et al.
Publicado: (2009)

High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Xu, Ya-ping, et al.
Publicado: (2021)

Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line
por: Barshishat, M, et al.
Publicado: (2002)

CD44 expression in patients with combined hepatocellular cholangiocarcinoma
por: Kim, Ryounggo, et al.
Publicado: (2015)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling
por: Peng, Rui, et al.
Publicado: (2018)

Hemostasis and inflammation: two of a kind?
por: Verhamme, Peter, et al.
Publicado: (2009)

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010)

SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma
por: Ning, Shanglei, et al.
Publicado: (2018)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Recurrent Intrahepatic Cholangiocarcinoma – Review
por: Bekki, Yuki, et al.
Publicado: (2021)

Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
por: Borakati, Aditya, et al.
Publicado: (2022)

Surgical Aspects of Intrahepatic Cholangiocarcinoma
por: Kupietzky, Amram, et al.
Publicado: (2022)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
por: Owen, Mackenzie, et al.
Publicado: (2023)

Contrast-enhanced Ultrasound Features of Intrahepatic Cholangiocarcinoma: A New Perspective
por: Chen, Tianjiao, et al.
Publicado: (2019)

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
por: Singh, Shweta, et al.
Publicado: (2022)

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Intrahepatic cholangiocarcinoma arising in Caroli's disease
por: Jang, Min Hye, et al.
Publicado: (2014)

The role of microRNAs in intrahepatic cholangiocarcinoma
por: Li, Zheng, et al.
Publicado: (2016)

Prostatic metastasis from intrahepatic cholangiocarcinoma
por: Tosev, Georgi, et al.
Publicado: (2018)

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017)

Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Massarweh, Nader N., et al.
Publicado: (2017)

Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma
por: Akateh, Clifford, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9d392vohfdh1nsnikqgjn0929q